Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | David R. Spigel, Martin J. Edelman, Kenneth O'Byrne, Luis Paz-Ares, David S. Shames, Wei Yu, Virginia E. Paton, Tony Mok | ||||||||||||
Title | Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. | ||||||||||||
|
|||||||||||||
URL | http://meetinglibrary.asco.org/content/128045-144 | ||||||||||||
Abstract Text | J Clin Oncol 32:5s, 2014 (suppl; abstr 8000) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|